These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2138064)

  • 1. Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
    Viner CV; Selby PJ; Zulian GB; Gore ME; Butcher ME; Wootton CM; McElwain TJ
    Cancer Chemother Pharmacol; 1990; 25(6):449-53. PubMed ID: 2138064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.
    Bechtel T; McBride A; Crawford B; Bullington S; Hofmeister CC; Benson DM; Jaglowski S; Penza S; Andritsos LA; Devine SM
    Support Care Cancer; 2014 Nov; 22(11):2911-6. PubMed ID: 24838259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
    Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
    J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ondansetron. Therapeutic use as an antiemetic.
    Milne RJ; Heel RC
    Drugs; 1991 Apr; 41(4):574-95. PubMed ID: 1711961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
    Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Ohta J; Akasaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1333-45. PubMed ID: 1386975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist.
    Leeser J; Lip H
    Anesth Analg; 1991 Jun; 72(6):751-5. PubMed ID: 1827966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
    Green JA; Watkin SW; Hammond P; Griggs J; Challoner T
    Cancer Chemother Pharmacol; 1989; 24(2):137-9. PubMed ID: 2525078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.
    Pinkerton CR; Williams D; Wootton C; Meller ST; McElwain TJ
    Arch Dis Child; 1990 Aug; 65(8):822-5. PubMed ID: 2144721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
    Suminaga M; Furue H; Taguchi T; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1879-90. PubMed ID: 1387774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia.
    Carden PA; Mitchell SL; Waters KD; Tiedemann K; Ekert H
    J Clin Oncol; 1990 Sep; 8(9):1531-5. PubMed ID: 2144019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
    Khojasteh A; Sartiano G; Tapazoglou E; Lester E; Gandara D; Bernard S; Finn A
    Cancer; 1990 Sep; 66(6):1101-5. PubMed ID: 2144788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
    Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
    Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
    Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1347-57. PubMed ID: 1386976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.